This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 Tumor Proportion Score.

Administered By

Awarded By

Contributors

Start/End

  • February 26, 2021 - February 28, 2026